Phobic Disorders

Phobic Disorders

No Results

No Results

processing….

Collectively, phobic disorders (including social anxiety disorder [social phobia], specific phobia, and agoraphobia) are the most common forms of psychiatric illness, surpassing the rates of mood disorders and substance abuse. Severity can range from mild and unobtrusive to severe and can result in incapacity to work, travel, or interact with others.

In obtaining a history from a patient with symptoms of a phobic disorder, the physician should inquire about the following:

Other anxiety disorders

Depression

Suicidal ideation

Substance-related disorders

Caffeine intake

Alcohol intake

Difficulties in social situations (in suspected social anxiety disorder)

Irrational and out-of-proportion fear or avoidance of particular objects or situations (in suspected specific phobia)

Intense anxiety reactions with exposure to specific situations (in suspected agoraphobia)

Anxiety is the most common feature in phobic disorders. Manifestations include the following:

Sweating

Palpitations

Elevated blood pressure

Elevated heart rate

Dyspnea

Dizziness

Tremor

Diarrhea

Paresthesias

Because anxiety manifests with a number of physical symptoms, any patient who presents with a de novo complaint of physical symptoms suggestive of an anxiety disorder should undergo a physical examination to help rule out medical conditions that might present with anxietylike symptoms.

For a patient with a suspected phobic disorder, the mental status examination should assess the following:

Appearance

Behavior

Ability to cooperate with the examination

Level of activity

Speech

Mood and affect

Thought processes and content

Insight

Judgment

Findings in a patient with a phobic disorder may include the following:

Psychomotor agitation, restlessness

Diaphoresis

Anxious mood and affect upon abrupt confrontation with the object of the phobia

Ability to identify the reason for the anxiety

Thought content significant for phobic ideation (unrealistic and out-of-proportion fears)

Preserved insight (usually; may be impaired, especially during exposure)

If comorbid conditions are present, possible suicidal or homicidal ideation

See Presentation for more detail.

To rule out anxiety secondary to medical conditions, the following tests may be helpful:

Thyroid function tests

Fasting glucose

Calcium

24-hour urine for 5-hydroxyindoleacetic acid (5-HIAA)

Drug screen

Electrocardiography (ECG) and cardiac enzyme tests

Electroencephalography (EEG) – Seizure disorders (these conditions may mimic anxiety)

Where another medical illness, such as a seizure disorder, is suspected, the following Imaging studies may be considered:

Head computed tomography (CT) 

Head magnetic resonance imaging (MRI)

Head positron emission tomography (PET)

Cardiac echocardiography

See Workup for more detail.

Treatment of phobic disorders usually consists of pharmacotherapy, psychotherapy, or some combination thereof.

Pharmacotherapy for social anxiety disorder may include the following:

Paroxetine and sertraline (FDA-approved)

Venlafaxine (FDA-approved)

Escitalopram, citalopram, fluoxetine, and fluvoxamine

Phenelzine

Moclobemide (not approved in the United States)

Tricyclic antidepressants (TCAs)

Beta-blockers (eg, propranolol)

Selected anticonvulsants (eg, gabapentin, pregabalin, valproic acid, topiramate, and tiagabine)

No controlled studies have demonstrated the efficacy of psychopharmacologic intervention for specific phobias. As-needed administration of a short-acting benzodiazepine may be useful for temporary anxiety relief in specific situations.

Agents that may be considered for agoraphobia include the following:

SSRIs (eg, escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline),

Venlafaxine and reboxetine

Some TCAs (eg, clomipramine and imipramine)

Some benzodiazepines (eg, alprazolam, lorazepam, diazepam, and clonazepam)

Mirtazapine

Moclobemide

Psychotherapeutic interventions that may be helpful for treating phobic disorders include the following:

Social anxiety disorder (social phobia) – Self-exposure monotherapy, computer-based exposure training, clinician-led exposure, or combination therapies (eg, self-exposure and cognitive-behavioral therapy (CBT)/self-help manual)

Specific phobia – CBT-based approach, including gradual desensitization; relaxation and breathing control techniques; exposure therapy

Agoraphobia – Combination of exposure therapy, relaxation, and breathing retraining

See Treatment and Medication for more detail.

A phobia is defined as an irrational fear that produces a conscious avoidance of the feared subject, activity, or situation. The affected person usually recognizes that the reaction is excessive.

Collectively, phobic disorders are the most common forms of psychiatric illness, surpassing the rates of mood disorders and substance abuse. Severity can range from mild and unobtrusive to severe and can result in incapacity to work, travel, or interact with others.

Treatment of phobic disorders usually consists of pharmacotherapy, psychotherapy, or some combination thereof. As a rule, a selected medication regimen should be continued for at least 6-12 months. If the symptoms have resolved and the patient is not experiencing excessive stress, the physician can gradually taper the patient off the medication. Psychotherapy usually helps make the transition away from medication more successful.

According to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), phobic disorders are no longer a distinct group of anxiety disorders; [1] nonetheless, they may still constitute a useful conceptual category. The 3 diagnoses that may be thought of as belonging to this category are as follows:

Social anxiety disorder (social phobia) – A strong, persisting fear of an interpersonal situation in which embarrassment can occur

Specific phobia – An overwhelming, persisting fear of an object or situation; it differs from other anxiety disorders in that the fear and anxiety is induced by the presence of the phobic situation or object

Agoraphobia – The fear of being alone in public places, particularly places from which a rapid exit would be difficult or help might not be available in the course of a panic attack or other embarrassing symptoms

Social anxiety disorder (social phobia)

The specific DSM-5 criteria for social anxiety disorder (social phobia) are as follows [1] :

Marked fear or anxiety about 1 or more social situations in which the individual might be scrutinized by others, such as social interactions (eg, having a conversation or meeting unfamiliar people), being observed (eg, eating or drinking), and performing in front of others (eg, giving a speech); in children, the anxiety may occur in peer settings and not just during interactions with adults

The individual fears acting in a way or showing anxiety symptoms that will be negatively evaluated (eg, will be humiliating or embarrassing, will lead to rejection, or will offend others)

The social situation almost always provokes immediate fear or anxiety; in children, anxiety may be expressed by crying, tantrums, freezing, clinging shrinking, or failing to speak in social situations

The social situations are actively avoided or endured with intense fear or anxiety

The fear or anxiety is out of proportion to the actual threat posed by the social situation and to the sociocultural context

The fear, anxiety, or avoidance persists, typically for 6 months or longer

The fear, anxiety or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning

The fear, anxiety or avoidance cannot be attributed to the physiologic effects of a substance (eg, a drug of abuse or medication) or another medical condition

The fear, anxiety or avoidance cannot be better explained by the symptoms of another mental disorder (eg, panic disorder, body dysmorphic disorder, or autism spectrum disorder)

If another medical condition (eg, Parkinson disease, obesity, or disfigurement caused by a burn or injury) is present, the fear, anxiety, or avoidance is clearly unrelated or is excessive

Performance-only subtype is specified when fear is restricted to speaking or performing in public. Individuals with performance-only social phobia do not fear or avoid nonperformance in generic social situations; their phobic reaction is typically restricted to professional performance (eg, musicians, dancers, performers, or athletes or public speaking).

Specific phobia

The specific DSM-5 criteria for specific phobia are as follows [1] :

Marked fear or anxiety about a specific object or situation (eg, flying, heights, animals, receiving an injection, or seeing blood); in children, this fear or anxiety may be expressed by crying, tantrums, freezing or clinging

The phobic object or situation almost always provokes immediate fear or anxiety

The phobic object or situation is actively avoided or endured with intense fear or anxiety

The fear or anxiety is out of proportion to the actual danger posed by the specific object or situation and to the sociocultural context

The fear, anxiety, or avoidance persists, typically for 6 months or longer

The fear, anxiety or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning

The disturbance cannot be better explained by the symptoms of another mental disorder, including fear, anxiety, and avoidance of situations associated with paniclike symptoms or other incapacitating symptoms (as in agoraphobia); objects or situations related to obsessions (as in obsessive-compulsive disorder [OCD]); reminders of traumatic events (as in posttraumatic stress disorder [PTSD]); separation from home or attachment figures (as in separation anxiety disorder); or social situations (as in social anxiety disorder)

The following specifiers are used, according to the phobic stimulus present [1] :

Animal – Fear of dogs (cynophobia), cats (ailurophobia), bees (apiphobia), spiders (arachnophobia), snakes (ophidiophobia), or other animals

Natural environment – Fear of heights (acrophobia), water (hydrophobia), or thunderstorms (astraphobia)

Blood-injection-injury – Fear of needles or invasive medical procedures

Situational – Fear of flying, elevators, or enclosed spaces

Other – Fear of situations that may lead to choking or vomiting; in children, loud sounds or costumed characters

Many individuals have multiple specific phobias. The average individual with specific phobia fears 3 objects or situations, and approximately 75% of individuals with specific phobia fear more than 1 situation or object. In such instances, multiple specific phobia diagnoses, each with its own diagnostic code reflecting the phobic stimulus, should be applied.

Agoraphobia

The specific DSM-5 criteria for agoraphobia are as follows [1] :

Marked fear or anxiety about at least 2 of the following 5 situations: (1) using public transportation (e.g. automobiles, buses, trains, ships, or planes), (2) being in open spaces (eg, parking lots, marketplaces, or bridges), (3) being in enclosed places (eg, shops, theaters, or cinemas), (4) standing in line or being in a crowd, and (5) being outside the home alone

The individual avoids these situations because of thoughts that escape might be difficult or help unavailable if paniclike symptoms or other embarrassing symptoms (eg, fear of falling in the elderly or fear of incontinence) should develop

The agoraphobic situations almost always provokes immediate fear or anxiety

The agoraphobic situations are actively avoided, necessitate the presence of a companion, or are endured with intense fear or anxiety

The fear or anxiety is out of proportion to the actual threat posed by the agoraphobic situation and to the sociocultural context

The fear, anxiety, or avoidance persists, typically for 6 months or longer

The fear, anxiety or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning

If another medical condition (eg, inflammatory bowel disease or Parkinson disease) is present, the fear, anxiety, or avoidance is clearly excessive

The fear, anxiety, or avoidance cannot be better explained by the symptoms of another mental disorder—for example, the symptoms are not confined to specific phobia, situational type; do not involve only social situations (as in social anxiety disorder); are not related exclusively to obsessions (as in OCD), perceived defects or flaws in physical appearance (as in body dysmorphic disorder), reminders of traumatic events (as in PTSD), or fear of separation (as in separation anxiety disorder)

Although agoraphobia may be associated with panic disorder, it is diagnosed irrespective of the presence of panic disorder. In cases where the presentation meets the criteria for both panic disorder and agoraphobia, both diagnoses should be applied.

Several biologic theories are postulated for the pathogenesis of phobic disorders, most focusing on the dysregulation of endogenous biogenic amines. Sympathetic nervous system activation is common in phobic disorders, resulting in elevations in heart rate and blood pressure, as well as symptoms such as tremor, palpitations, sweating, dyspnea, dizziness, and paresthesias. [2]

Genetic factors seem to play a role in both social anxiety disorder (social phobia) and specific phobia. On the basis of family and twin studies, the risks for specific phobia and social anxiety disorder appear to be moderately heritable. [3, 4, 5]

Preliminary neuroimaging evidence indicates that while different patterns of brain activation might be associated with the different phobias, [6]  there is an overall increased activation in the prefrontal and orbitofrontal cortex, anterior cingulate cortex, insula, and amygdala in phobic patients exposed to phobia-related triggers compared with healthy controls. [7]

Psychological theories range from explaining anxiety as a displacement of an intrapsychic conflict (psychodynamic models) to conditioning (learned) paradigms (cognitive-behavior models). Many of these theories capture portions of the disorder.

A behaviorist would see phobia as a learned, conditioned response resulting from a past association with a situation that had negative emotional valence at the time of association (eg, social situations are avoided because intense anxiety was originally experienced in that setting). Even if no danger is posed in most social encounters, an avoidance response has been linked to these situations. Treatment from this perspective aims to weaken and eventually separate the specific response from the stimulus.

A psychoanalyst would likely conceptualize social anxiety as a symptom of a deeper conflict—for instance, low self-esteem or unresolved conflicts with internal objects. The treatment uses exploration with the goal of understanding the underlying conflict.

Neurobiologic and psychological theories, as well as familial patterns, have contributed to understanding the underlying causes of phobic disorders.

Social anxiety disorder (social phobia)

Positron emission tomography (PET) has shown lower serotonin (5-HT) 1A binding in the amygdala and mesiofrontal areas, and negative correlations between cortisol plasma levels and 5-HT1A binding in the amygdala, hippocampus, and retrosplenial cortex have been reported in patients with social anxiety disorder. [8, 9]

A review of 48 neuroimaging articles involving social anxiety disorder concluded that increased activity in the limbic and paralimbic regions is the most consistent finding (across imaging techniques) in social anxiety disorder. [10]

Further, increased connectivity in the salience network, including the dorsal anterior cingulate cortex, anterior insula, and amygdala have been consistently associated with SAD. [11]

Specific phobia

Phobic reactions may result from activation of object recognition and emotional processing areas occurring in conjunction with inhibition of the prefrontal areas that are responsible for cognitive control over emotion-triggering. [12]

In a meta-analysis reviewing data from 13 studies including 327 subjects, there was increased activation in the left amygdala/globus pallidus, left insula, right thalamus (pulvinar), and cerebellum in response to phobic stimuli. Further, widespread deactivation of the right frontal cortex, limbic cortex, basal ganglia, and cerebellum, with increased activation detected in the thalamus, followed exposure-based therapy. [13] While these results suggest a common neuroanatomy for specific phobias, other data suggest partially distinct neurobiologic substrates for different types of phobias. 

Social anxiety disorder can be initiated by traumatic social experience (eg, embarrassment) or by social-skills deficits that produce recurring negative experiences. Hypersensitivity to rejection, perhaps related to serotonergic or dopaminergic dysfunction, is present. It is theorized that social anxiety disorder represents an interaction between biologic and genetic factors and environmental events.

Specific phobia can be acquired through conditioning, modeling, or a traumatic experience; it may even have a genetic component (eg, blood-injury phobia).

Agoraphobia may be the result of repeated and unexpected panic attacks, which, in turn, may be linked to cognitive distortions, conditioned responses, or abnormalities in noradrenergic, serotonergic, or gamma-aminobutyric acid (GABA)–related neurotransmission.

A familial pattern has been reported for both social anxiety disorder and specific phobia. Generalized social anxiety disorder further increases the risk of familial transmission. With respect to specific phobia, first-degree relatives appear to have an increased risk for the subtype of the phobia rather than for the specific trigger. For example, a given family may exhibit an increased rate of animal phobias rather than share a phobia of a specific animal. [1]

The 12-month prevalence rates for the United States are estimated as follows [14] :

Social anxiety disorder (social phobia) – 7%

Specific phobia – 7-9%

Agoraphobia – 1.7%

Social anxiety disorder appears to be less common in much of the world than it is in the United States, with 12-month prevalence estimates clustering in the range of 0.5-2.0%; median prevalence in Europe is 2.3%. Prevalence estimates for specific phobia in European countries are close to those in the United States (~6%) but are generally lower in Asian, African, and Latin American countries (2-4%). [15]

In the United States, social anxiety disorder tends to start early in life, with 75% of the patients experiencing its onset between ages 8 and 15 years and a median age at onset of 13 years. [16] The 12-month prevalence estimates for social anxiety disorder in children and adolescents are comparable to those in adults. [14] Prevalence decreases with advancing age [17] ; the 12-month prevalence for older adults is in approximately 7%. [14, 18]

In general, specific phobia appears earlier than either social anxiety disorder or agoraphobia does. Most such phobias develop during childhood and eventually disappear. The estimated prevalence of specific phobia is approximately 5% in younger children [19] and 16% in children aged 13-17 years. [14] The prevalence is lower (3-5%) in older individuals, possibly reflecting a decrease in severity to subclinical levels. [14]

The 12-month prevalence of agoraphobia in adolescents and adults is approximately 1.7%. [14, 20] Agoraphobia may occur in childhood, but the incidence peaks in late adolescence and early adulthood. [21] The 12-month prevalence in individuals older than 65 years is 0.4%. [22]

The phobic disorders appear to have a higher incidence among women. Higher rates of social anxiety disorder are found in females in the general population (with female-to-male ratios ranging from 1.5:1 to 2.2:1), [23] and the sex difference in prevalence is more pronounced in adolescents and young adults. [24]

Females are more frequently affected by specific phobia than males, at a rate of approximately 2:1, though rates vary across different phobic stimuli. Animal, natural environment, and situational specific phobias are predominately experienced by females, whereas blood-injection-injury phobia is experienced equally by the 2 sexes. [6]

Agoraphobia has a female-to-male ratio of 2-3:1. [25]

The prevalence of social anxiety disorder in the United States is higher in American Indians and lower in persons of Asian, Latino, African American, and Afro-Caribbean descent as compared with non-Hispanic white individuals. Prevalence figures for specific phobia and agoraphobia appear not to vary substantially across cultural or racial groups. [15]

Most patients respond to treatment, with good resolution of symptoms. Patients with specific phobia often regain the highest level of functioning, whereas those with agoraphobia or social anxiety disorders may have residual symptoms or run a greater risk of relapse even after successful treatment. In fact, patients with social anxiety disorders with extensive deficits in social skills may not respond well to treatment; in one study, social anxiety disorder had the smallest probability of recovery after 12 years of follow-up. [26]

The data on the course of social anxiety disorder (SAD) varies between 3% and 80% in retrospective studies and 36% and 93% in prospective studies, suggesting that SAD can have a short or fluctuating course in addition to a chronic course. [27]  Limited data indicate a chronic lifetime course for untreated specific phobias. [28]  A meta-analysis of 33 randomized exposure-based interventions showed that with treatment, the prognosis of specific phobias is good. [29]

The prognosis is determined by several factors, including the following:

Severity of diagnosis

level of functioning before onset of symptoms

Degree of motivation for treatment

level of support (eg, from family, friends, work, or school)

Ability to comply with medication regimens, psychotherapeutic regimens, or both

Considerable evidence shows that social anxiety disorder results in significant functional impairment and decreased quality of life. [30, 31] Despite evidence of impairment, only a minority of individuals with specific phobia ever seek professional treatment.

Phobias are highly comorbid, social anxiety disorder in particular. Most comorbid social anxiety disorders and specific phobias are temporally primary, whereas most comorbid agoraphobia is temporally secondary. Comorbid phobias are generally more severe than pure phobias. Social anxiety disorder is also frequently comorbid with major depressive disorder (MDD) and atypical depression, which results in increased disability. [31, 32]

There has been some controversy regarding whether anxiety disorders in general and phobic disorders in particular are independently associated with suicidal ideation and suicide attempts (ie, after comorbid mental disorders are adjusted for).

Current evidence suggests that even after adjustment for sociodemographic factors and other mental disorders, the baseline presence of any anxiety disorder—including agoraphobia, social anxiety disorder, and specific phobia—is significantly associated with suicidal ideation and suicide attempts. Additionally, the presence of any anxiety disorder(again, including any phobic disorder) in combination with a mood disorder appears to increase the likelihood of suicide attempts over what would be expected with a mood disorder alone. [33]

Significant morbidity is also possible in terms of work and relationships, especially in social phobia and agoraphobia. Patients with severe agoraphobia may be housebound and therefore unable to seek out medical attention when needed. Patients with concomitant panic attacks are at higher risk for substance abuse and suicide.

The treating physician should begin a process of education, not only for the patient but also for family and friends who may be confused about the diagnosis and the need for treatment.

Commonplace abilities such as socializing at gatherings or riding in a small elevator are taken for granted by most people, but patients who experience phobias may have tremendous difficulty in these areas and can be greatly helped significantly by a caring support system. Family and friends can encourage patients to confront fears and help them when necessary (eg, with medication compliance); they can also assist by learning when to stay out of the way and allow patients to venture forth on their own.

Numerous books and self-help groups are available. In addition, patient advocacy groups exist nationwide that provide patients with information, give presentations, and hold conferences. The following Web sites are helpful:

Social Phobia/Social Anxiety Association

American Psychiatric Association

Anxiety Disorders Association of America

MedlinePlus, Phobias

MayoClinic.com, Phobias

US Food and Drug Administration (FDA), Fighting Phobias, The Things That Go Bump in the Mind

For patient education information, see the Mental Health Center, as well as Anxiety, Panic Attacks, and Hyperventilation.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association Press; 2000.

Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry. 2001 Oct. 158(10):1558-67. [Medline].

Kendler KS, Karkowski LM, Prescott CA. Fears and phobias: reliability and heritability. Psychol Med. 1999 May. 29(3):539-53. [Medline].

Fyer AJ, Mannuzza S, Chapman TF, Liebowitz MR, Klein DF. A direct interview family study of social phobia. Arch Gen Psychiatry. 1993 Apr. 50(4):286-93. [Medline].

Van Houtem CM, Laine ML, Boomsma DI, Ligthart L, van Wijk AJ, De Jongh A. A review and meta-analysis of the heritability of specific phobia subtypes and corresponding fears. J Anxiety Disord. 2013 May. 27(4):379-88. [Medline].

LeBeau RT, Glenn D, Liao B, et al. Specific phobia: a review of DSM-IV specific phobia and preliminary recommendations for DSM-V. Depress Anxiety. 2010 Feb. 27(2):148-67. [Medline].

Linares IM, Trzesniak C, Chagas MH, Hallak JE, Nardi AE, Crippa JA. Neuroimaging in specific phobia disorder: a systematic review of the literature. Rev Bras Psiquiatr. 2012 Mar. 34(1):101-11. [Medline].

Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry. 2007 May 1. 61(9):1081-9. [Medline].

Lanzenberger R, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien LK, et al. Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. Int J Neuropsychopharmacol. 2010 Oct. 13(9):1129-43. [Medline].

Freitas-Ferrari MC, Hallak JE, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas MH, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30. 34(4):565-80. [Medline].

Kim YK, Yoon HK. Common and distinct brain networks underlying panic and social anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3. 80 (Pt B):115-122. [Medline].

Ahs F, Pissiota A, Michelgård A, Frans O, Furmark T, Appel L, et al. Disentangling the web of fear: amygdala reactivity and functional connectivity in spider and snake phobia. Psychiatry Res. 2009 May 15. 172(2):103-8. [Medline].

Kim YK, Yoon HK. Common and distinct brain networks underlying panic and social anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3. 80 (Pt B):115-122. [Medline].

Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012 Sep. 21(3):169-84. [Medline]. [Full Text].

Lewis-Fernández R, Hinton DE, Laria AJ, et al. Culture and the anxiety disorders: recommendations for DSM-V. Depress Anxiety. 2010 Feb. 27(2):212-29. [Medline].

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun. 62(6):593-602. [Medline].

Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety disorders in older adults: a comprehensive review. Depress Anxiety. 2010 Feb. 27(2):190-211. [Medline].

Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008 Jan. 38(1):15-28. [Medline]. [Full Text].

Ollendick TH, King NJ, Muris P. Fears and phobias in children: phenomenology, epidemiology and aetiology. Child Adolesc Ment Health. 2002. 7:98–106.

Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep. 21(9):655-79. [Medline].

Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am. 2009 Sep. 32(3):483-524. [Medline]. [Full Text].

Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006 Apr. 63(4):415-24. [Medline]. [Full Text].

Fehm L, Pelissolo A, Furmark T, Wittchen HU. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005 Aug. 15(4):453-62. [Medline].

Wittchen HU, Stein MB, Kessler RC. Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity. Psychol Med. 1999 Mar. 29(2):309-23. [Medline].

Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG. Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010 Feb. 27(2):113-33. [Medline].

Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005 Jun. 162(6):1179-87. [Medline].

Vriends N, Bolt OC, Kunz SM. Social anxiety disorder, a lifelong disorder? A review of the spontaneous remission and its predictors. Acta Psychiatr Scand. 2014 Aug. 130 (2):109-22. [Medline].

Sigström R, Östling S, Karlsson B, Waern M, Gustafson D, Skoog I. A population-based study on phobic fears and DSM-IV specific phobia in 70-year olds. J Anxiety Disord. 2011 Jan. 25 (1):148-53. [Medline].

Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008 Jul. 28 (6):1021-37. [Medline].

Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994 Aug. 55(8):322-31. [Medline].

Lochner C, Mogotsi M, du Toit PL, Kaminer D, Niehaus DJ, Stein DJ. Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology. 2003 Sep-Oct. 36(5):255-62. [Medline].

Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry. 2003 Aug. 60(8):817-26. [Medline].

Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005 Nov. 62(11):1249-57. [Medline].

Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29. 371(9618):1115-25. [Medline].

Beesdo K, Bittner A, Pine DS, Stein MB, Höfler M, Lieb R, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007 Aug. 64(8):903-12. [Medline].

Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996 Feb. 53(2):159-68. [Medline].

Liotti G. Phobias of Attachment-Related Inner States in the Psychotherapy of Adult Survivors of Childhood Complex Trauma. J Clin Psychol. 2013 Aug 28. [Medline].

Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov. 19(6):567-96. [Medline].

de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatr Scand. 1999 Jan. 99(1):59-67. [Medline].

Pelissolo A. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Encephale. 2008 Sep. 34(4):400-8. [Medline].

National Prescribing Service Limited. Escitalopram (Lexapro, Esipram) for generalised anxiety disorder and social anxiety disorder (social phobia). NPS RADAR. Available at http://bit.ly/dOARMJ.

Stein DJ, Ipser JC, van Balkom AJ. Pharmacotherapy for social anxiety disorder. Cochrane Review. Chichester, UK: John Wiley and Sons, Ltd; 2009.

Westenberg HG. Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009 Feb. 14(2 Suppl 3):24-33. [Medline].

Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010 Jul. 71(7):839-54. [Medline].

Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us?. J Clin Psychiatry. 2006. 67 Suppl 12:20-6. [Medline].

Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis. Psychother Psychosom. 2013 Sep 20. 82(6):355-362. [Medline].

Van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, et al. WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug. 8(8 Suppl 1):40-52. [Medline].

Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry. 1998 May. 155(5 Suppl):1-34. [Medline].

Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998 Sep. 155(9):1189-95. [Medline].

Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 Nov. 155(11):1570-7. [Medline].

Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety. 1999. 9(3):107-16. [Medline].

Shear MK, Beidel DC. Psychotherapy in the overall management strategy for social anxiety disorder. J Clin Psychiatry. 1998. 59 Suppl 17:39-46. [Medline].

[Guideline] Mayor S. NICE advocates computerised CBT. BMJ. 2006 Mar 4. 332(7540):504. [Medline]. [Full Text].

Barlow JH, Ellard DR, Hainsworth JM, Jones FR, Fisher A. A review of self-management interventions for panic disorders, phobias and obsessive-compulsive disorders. Acta Psychiatr Scand. 2005 Apr. 111(4):272-85. [Medline].

Masia Warner C, Fisher PH, Shrout PE, Rathor S, Klein RG. Treating adolescents with social anxiety disorder in school: an attention control trial. J Child Psychol Psychiatry. 2007 Jul. 48(7):676-86. [Medline].

Bunnell BE, Beidel DC, Mesa F. A Randomized Trial of Attention Training for Generalized Social Phobia: Does Attention Training Change Social Behavior?. Behav Ther. 2013 Dec. 44(4):662-673. [Medline].

Ayala ES, Meuret AE, Ritz T. Treatments for blood-injury-injection phobia: a critical review of current evidence. J Psychiatr Res. 2009 Oct. 43(15):1235-42. [Medline].

Rothbaum BO, Anderson P, Zimand E, Hodges L, Lang D, Wilson J. Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther. 2006 Mar. 37(1):80-90. [Medline].

Paquette V, Lévesque J, Mensour B, Leroux JM, Beaudoin G, Bourgouin P, et al. “Change the mind and you change the brain”: effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage. 2003 Feb. 18(2):401-9. [Medline].

Schienle A, Schäfer A, Hermann A, Rohrmann S, Vaitl D. Symptom provocation and reduction in patients suffering from spider phobia: an fMRI study on exposure therapy. Eur Arch Psychiatry Clin Neurosci. 2007 Dec. 257(8):486-93. [Medline].

Sánchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, Gómez-Conesa A. Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev. 2010 Feb. 30(1):37-50. [Medline].

Hudson C, Hudson S, MacKenzie J. Protein-source tryptophan as an efficacious treatment for social anxiety disorder: a pilot study. Can J Physiol Pharmacol. 2007 Sep. 85(9):928-32. [Medline].

Straube T, Mentzel HJ, Miltner WH. Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. Neuroimage. 2007 Oct 1. 37(4):1427-36. [Medline].

Adrian Preda, MD Professor of Clinical Psychiatry and Human Behavior, University of California, Irvine, School of Medicine

Adrian Preda, MD is a member of the following medical societies: American Association for the Advancement of Science, American Psychiatric Association, International College of Neuropsychopharmacology, International Congress of Schizophrenia Research, Schizophrenia International Research Society, Society of Biological Psychiatry

Disclosure: Nothing to disclose.

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.

Mohammed A Memon, MD Chairman and Attending Geriatric Psychiatrist, Department of Psychiatry, Spartanburg Regional Medical Center

Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, and American Psychiatric Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Phobic Disorders

Research & References of Phobic Disorders|A&C Accounting And Tax Services
Source